Literature DB >> 20476860

Contribution of anti-CCP antibodies, proximal interphalangeal joint involvement, HLA-DRB1 shared epitope, and PADI4 as risk factors for the development of rheumatoid arthritis in palindromic rheumatism.

M Tamai1, A Kawakami, N Iwamoto, K Arima, K Aoyagi, K Eguchi.   

Abstract

OBJECTIVES: To determine which variables at baseline are predictive for the development of rheumatoid arthritis (RA) from palindromic rheumatism (PR) in a Japanese population.
METHODS: Anti-cyclic citrullinated peptide (anti-CCP) antibodies, joint involvement pattern, genotypes of HLA-DRB1, peptidylarginine deiminase (PADI4), and protein tyrosine phosphatase (PTPN22) were examined in 28 patients with PR at baseline, and their clinical outcome was prospectively evaluated. The same variables were also investigated in 38 healthy controls.
RESULTS: Eleven out of 28 patients with PR developed RA. The prevalence of anti-CCP antibodies in the PR patients who developed RA was significantly higher compared to the patients who did not. Proximal interphalangeal (PIP) joint involvement at baseline was also predictive towards the development of RA. Compared with the controls, differences in the frequency of single-nucleotide polymorphism (SNP) on padi4_104 [T(RA susceptible)-->C(RA non-susceptible)] and the presence of an RA susceptible homozygote of the PADI4 haplotype were detected in patients with PR whereas we could not find any further difference in PR patients who developed RA compared to PR patients who do not develop RA in PADI4. None of the subjects possessed the PTPN22 SNP (1858C-->T). Cox regression analysis revealed that anti-CCP antibodies as well as PIP involvement are the most relevant variables for the development of RA from PR. None of the PR patients with either HLA-DRB1*SE alleles (or the HLA-DRB1*0405 allele) or anti-CCP antibodies developed RA.
CONCLUSIONS: Anti-CCP antibodies, in relation to HLA-DRB1*SE carriership, and PIP involvement are predictive for the development of RA from PR in the Japanese population.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20476860     DOI: 10.3109/03009741003604534

Source DB:  PubMed          Journal:  Scand J Rheumatol        ISSN: 0300-9742            Impact factor:   3.641


  7 in total

1.  In palindromic rheumatism, hand joint involvement and positive anti-CCP antibodies predict RA development after 1 year of follow-up.

Authors:  Yasser Emad; Ashraf Anbar; Ihab Abo-Elyoun; Nashwa El-Shaarawy; Hadeel Al-Hanafi; Hatem Darwish; Mona Gamil; Johannes J Rasker
Journal:  Clin Rheumatol       Date:  2014-03-13       Impact factor: 2.980

Review 2.  Palindromic rheumatism as part of the rheumatoid arthritis continuum.

Authors:  Kulveer Mankia; Paul Emery
Journal:  Nat Rev Rheumatol       Date:  2019-10-08       Impact factor: 20.543

3.  Is palindromic rheumatism amongst children a benign disease?

Authors:  Yonatan Butbul-Aviel; Yosef Uziel; Nofar Hezkelo; Riva Brik; Gil Amarilyo
Journal:  Pediatr Rheumatol Online J       Date:  2018-02-13       Impact factor: 3.054

4.  Palindromic Rheumatism Frequently Precedes Early Rheumatoid Arthritis: Results From an Incident Cohort.

Authors:  L Ellingwood; O Schieir; M F Valois; S J Bartlett; L Bessette; G Boire; G Hazlewood; C Hitchon; E C Keystone; D Tin; C Thorne; V P Bykerk; J E Pope
Journal:  ACR Open Rheumatol       Date:  2019-10-21

5.  Palindromic Rheumatism: Just a Pre-rheumatoid Stage or Something Else?

Authors:  Raimon Sanmartí; Beatriz Frade-Sosa; Rosa Morlà; Raul Castellanos-Moreira; Sonia Cabrera-Villalba; Julio Ramirez; Georgina Salvador; Isabel Haro; Juan D Cañete
Journal:  Front Med (Lausanne)       Date:  2021-03-25

6.  A core set of risk factors in individuals at risk of rheumatoid arthritis: a systematic literature review informing the EULAR points to consider for conducting clinical trials and observational studies in individuals at risk of rheumatoid arthritis.

Authors:  Kulveer Mankia; Heidi Siddle; Andrea Di Matteo; Deshiré Alpízar-Rodríguez; Joel Kerry; Andreas Kerschbaumer; Daniel Aletaha; Paul Emery
Journal:  RMD Open       Date:  2021-09

7.  Elevated rheumatoid factor and long term risk of rheumatoid arthritis: a prospective cohort study.

Authors:  Sune F Nielsen; Stig E Bojesen; Peter Schnohr; Børge G Nordestgaard
Journal:  BMJ       Date:  2012-09-06
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.